Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document any history...
Rheumatic Heart Disease IV: Nursing Management01:20

Rheumatic Heart Disease IV: Nursing Management

AssessmentA comprehensive assessment is essential in managing a patient with rheumatic heart disease (RHD). Begin with obtaining a detailed medical history, including recent streptococcal infections, a history of rheumatic fever, or previously diagnosed rheumatic heart disease. Assess the patient for symptoms such as fever, chest pain, widespread joint pain (arthralgia), tachycardia, pericardial friction rub, muffled heart sounds, heart murmurs, peripheral edema, subcutaneous nodules, and...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Pericarditis III: Medical Management01:17

Pericarditis III: Medical Management

The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy and safety of riociguat in early pulmonary vascular disease (ESRA): a prospective, multicenter, randomized, double-blind, placebo-controlled phase IIa trial.

Chest·2026
Same author

Expert viewpoint on endpoints in systemic sclerosis: current and future outlook.

RMD open·2026
Same author

Expert recommendations for the management of fecal incontinence in systemic sclerosis: A report from the World Scleroderma Foundation (WSF) Gastrointestinal "Ad hoc committee".

Journal of scleroderma and related disorders·2026
Same author

Expert recommendations for the management of refractory gastroesophageal reflux disease in systemic sclerosis: A report from the World Scleroderma Foundation (WSF) Gastrointestinal "Ad hoc committee".

Journal of scleroderma and related disorders·2026
Same author

Real-World Safety and Effectiveness of JAK Inhibitors in Systemic Sclerosis: A Propensity-Matched Study From the EUSTAR Cohort.

Arthritis care & research·2026
Same author

Influence of comorbidities and patient demographics on Raynaud's symptom characteristics: implications for diagnosis and management.

Journal of scleroderma and related disorders·2026

Related Experiment Video

Updated: Jun 12, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

Evidence-based management of rapidly progressing systemic sclerosis.

Dinesh Khanna1, Christopher P Denton

  • 1UCLA Scleroderma Program, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. dkhanna@mednet.ucla.edu

Best Practice & Research. Clinical Rheumatology
|June 11, 2010
PubMed
Summary

Systemic sclerosis, an autoimmune disease with high mortality, presents treatment challenges. Emerging evidence supports current therapies and novel approaches for this condition.

Related Experiment Videos

Last Updated: Jun 12, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

Area of Science:

  • Rheumatology
  • Immunology
  • Internal Medicine

Background:

  • Systemic sclerosis (SSc) is an autoimmune rheumatic disease with high mortality and significant morbidity.
  • Limited therapeutic options and perceived lack of treatment efficacy have historically contributed to a nihilistic outlook in managing SSc.
  • The clinical landscape for SSc management is evolving with new data and emerging therapeutic strategies.

Purpose of the Study:

  • To review and discuss recent clinical trials in systemic sclerosis.
  • To highlight emerging data supporting current treatment approaches.
  • To explore novel therapeutic strategies entering the clinical arena for SSc.

Main Methods:

  • Review of recent clinical trial data in systemic sclerosis.
  • Discussion of evidence supporting existing treatments.
  • Analysis of novel and emerging SSc therapies.

Main Results:

  • Emerging data suggest efficacy for certain treatment approaches in systemic sclerosis.
  • Several novel therapeutic strategies are progressing towards clinical application.
  • Recent clinical trials provide valuable insights into SSc management.

Conclusions:

  • The management of systemic sclerosis is improving with new evidence and therapeutic options.
  • There is a growing optimism in treating systemic sclerosis due to advancements in research.
  • Continued research and clinical trials are crucial for advancing SSc care.